MarketCap
Alnylam Pharmaceuticals ALNY
$ 228.65
0.67%
Facebook
X
Telegram
Alnylam Pharmaceuticals Financial Ratios 2025-2007 | ALNY
Brief overview of Alnylam Pharmaceuticals's valuation multiples
The review covers five available annual periods spanning 2021 to 2025.
The current valuation set is P/S 10.99x (median 15.09x), P/B 51.71x (median 31.79x). Multiples are on average 17.7% above their own medians. A substantial share of positive expectations may already be priced in.
Capital efficiency is characterized by ROE 39.8%, ROA 6.3%, ROCE 63.6%. Profitability forms a strong profile, with capital and assets producing substantial returns.
PEG is 4.25x. Price is well ahead of embedded growth, making market expectations demanding.
The cash conversion cycle decreased 33.9 days to 46.6 days, supporting working-capital efficiency.
What the ratios show
Alnylam Pharmaceuticals's profitability supports higher multiples, although much of the quality is already reflected in price.
Annual Financial Ratios Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
130.1 | -122.0 | -42.3 | -21.0 | -21.9 | -19.8 | -14.2 | -10.8 | -24.2 | -7.7 | -20.0 | -19.3 | -59.3 | -11.3 | -8.2 | -14.9 | -18.5 | - | - |
P/S |
11.0 | 15.1 | 10.2 | 22.9 | 22.1 | 34.6 | 57.4 | 109.7 | 132.2 | 66.9 | 140.9 | 137.8 | 112.1 | 17.9 | 5.7 | - | - | - | - |
EPS |
2.4 | -2.2 | -3.5 | -9.3 | -7.2 | -7.5 | -8.1 | -7.6 | -5.4 | -4.8 | -3.5 | -4.8 | -1.4 | -2.1 | -1.4 | -1.0 | -1.1 | - | - |
EV (Enterprise Value) |
43.3 B | 37.1 B | 21.9 B | 26.6 B | 20.9 B | 18.9 B | 13 B | 8.07 B | 11.5 B | 3.31 B | 5.73 B | 7.04 B | 5.38 B | 1.3 B | 567 M | 808 M | 1.04 B | -192 M | -105 M |
EBITDA per Share |
4.25 | -0.94 | -1.83 | -6.09 | -5.58 | -6.9 | -8.1 | -8.03 | -5.37 | -4.78 | -3.3 | -2.32 | -1.34 | -1.08 | -1.17 | -0.93 | -1.01 | - | - |
EV/EBITDA |
77.8 | -308.9 | -95.9 | -35.9 | -31.5 | -22.5 | -13.6 | -9.7 | -23.2 | -7.6 | -20.3 | -40.0 | -63.3 | -21.0 | -8.1 | -20.6 | -24.8 | 8.7 | - |
PEG |
-0.96 | 4.25 | 2.25 | -4.12 | -3.82 | -1.07 | 2.0 | 0.27 | 1.84 | 0.2 | -0.69 | 0.08 | -1.89 | 0.2 | 0.27 | - | - | - | - |
P/B |
51.7 | 505.7 | -84.5 | -150.0 | 31.8 | 16.8 | 8.8 | 6.3 | 6.7 | 3.4 | 4.6 | 7.4 | 19.6 | 8.9 | 4.0 | 4.1 | 4.9 | - | - |
P/CF |
77.9 | -4082.0 | 178.9 | -43.8 | -29.1 | -27.7 | -30.1 | -11.9 | -24.4 | -8.5 | -28.7 | -39.9 | -72.8 | -9.7 | -5.4 | -7.7 | -12.2 | - | - |
ROE % |
39.76 | -414.62 | 199.53 | 714.91 | -144.99 | -84.46 | -61.59 | -58.49 | -27.79 | -44.57 | -22.94 | -38.49 | -33.00 | -79.08 | -48.86 | -27.50 | -26.74 | -12.99 | - |
ROA % |
6.32 | -6.56 | -11.49 | -31.90 | -23.41 | -25.19 | -37.00 | -48.36 | -24.61 | -32.48 | -20.92 | -33.38 | -21.22 | -36.87 | -20.45 | -11.07 | -9.89 | - | - |
ROCE % |
63.56 | -263.66 | 127.89 | 496.18 | -120.48 | -81.52 | -45.99 | -58.39 | -27.02 | -37.54 | -22.35 | -18.72 | -25.35 | -26.58 | -27.28 | -27.85 | -27.03 | -13.77 | - |
Current Ratio |
1.2 | 1.0 | 0.9 | 1.0 | 1.2 | 1.4 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | 4.7 | 2.6 | 1.9 | 1.7 | 1.6 | - | - |
DSO |
43.3 | 16.4 | 13.2 | 18.6 | 23.1 | 17.9 | 71.4 | 91.4 | 138.0 | 180.6 | 73.7 | 288.3 | 32.9 | 0.6 | 6.5 | - | - | - | - |
DIO |
43.5 | 99.8 | 148.4 | 280.3 | 256.4 | 323.6 | 820.6 | 4875.0 | - | - | - | - | - | - | - | - | - | - | - |
DPO |
55.0 | 85.7 | 104.5 | 223.3 | 199.0 | 250.6 | 726.5 | 12094.0 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
86.7 | 116.2 | 161.6 | 298.9 | 279.5 | 341.6 | 892.1 | 4966.4 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
31.7 | 30.6 | 57.0 | 75.6 | 80.5 | 91.0 | 165.6 | -7127.6 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Alnylam Pharmaceuticals
| 2026-Q2 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.23 | 1.91 | -0.51 | -0.44 | - | -0.87 | -0.13 | -0.52 | - | 1.18 | -2.21 | -1.4 | - | -3.32 | -2.29 | -2 | - | -1.72 | -1.61 | -1.71 | -2.09 | -2.18 | -1.56 | -1.62 | -2.47 | -1.92 | -2.02 | -1.73 | -2.09 | -2.43 | -1.63 | -1.41 | -1.48 | -1.34 | -1.34 | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 | -1.07 | -0.91 | -0.85 | -0.62 | -0.28 | -0.58 | -0.58 | -3.7 | -0.51 | -0.48 | -0.29 | -0.15 | -1.2 | -0.38 | -0.25 | -0.25 | -0.33 | -0.31 | -0.33 | -0.38 | - | - |
EBITDA per Share |
1.94 | 3.12 | - | 0.25 | - | - | - | -0.24 | - | - | - | -1.09 | - | -1.87 | -1.59 | -1.14 | - | -1.22 | -1.24 | -1.48 | - | -1.73 | -1.59 | -1.8 | - | -1.88 | -2.11 | -1.75 | - | -2.47 | -1.86 | -1.44 | - | -1.26 | -1.3 | -1.2 | - | -1.1 | -0.98 | -1.24 | - | -0.76 | -0.76 | -0.59 | - | -0.48 | -0.52 | -3.93 | - | -0.39 | -0.27 | -0.13 | - | -0.22 | -0.14 | -0.19 | - | -0.2 | -0.25 | -0.34 | -0.12 | -0.22 |
ROE % |
43.26 | -313.73 | 129.59 | 186.10 | 235.90 | 146.82 | 559.29 | 75.78 | 45.71 | 645.85 | 577.35 | 449.80 | 382.65 | 355.59 | -266.76 | -130.81 | -70.89 | -94.86 | -92.73 | -88.15 | -84.46 | -79.69 | -69.26 | -66.88 | -61.59 | -58.63 | -62.98 | -60.29 | -58.49 | -50.30 | -38.42 | -32.56 | -27.79 | -32.01 | -36.36 | -39.45 | -44.57 | -39.47 | -34.23 | -30.11 | -22.94 | -18.05 | -16.67 | -15.71 | -38.49 | -48.18 | -54.46 | -56.47 | -33.00 | -67.43 | -70.99 | -73.94 | -79.08 | -44.81 | -41.48 | -43.54 | -48.86 | -42.73 | -40.35 | -13.80 | -5.99 | -8.84 |
ROA % |
5.32 | -0.29 | -5.89 | -6.16 | -4.80 | -0.95 | -6.41 | -11.12 | -9.40 | -20.88 | -31.73 | -29.50 | -24.37 | -29.77 | -18.29 | -24.44 | -17.44 | -24.59 | -26.14 | -26.00 | -25.19 | -29.57 | -30.85 | -34.75 | -37.00 | -38.89 | -45.76 | -46.98 | -48.36 | -42.06 | -32.65 | -28.20 | -24.61 | -26.42 | -28.50 | -29.70 | -32.48 | -30.08 | -27.37 | -25.41 | -20.92 | -16.36 | -14.90 | -13.80 | -33.38 | -39.10 | -42.08 | -42.32 | -21.22 | -35.15 | -34.88 | -35.06 | -36.87 | -20.32 | -18.23 | -18.63 | -20.45 | -17.71 | -16.34 | -5.78 | -2.33 | -3.32 |
ROCE % |
183.62 | -71.17 | -1813.57 | -1787.30 | -1802.96 | -1931.90 | -1637.88 | 4.97 | -14.84 | 366.66 | 386.71 | 293.82 | 236.04 | 212.00 | -186.63 | -97.85 | -61.27 | -83.43 | -78.97 | -82.52 | -62.41 | -77.44 | -71.70 | -65.26 | -44.58 | -64.13 | -63.87 | -58.77 | -45.65 | -52.77 | -40.04 | -31.29 | -19.97 | -31.56 | -34.49 | -39.63 | -33.60 | -39.79 | -33.96 | -28.05 | -16.09 | -20.92 | -19.53 | -42.50 | -38.37 | -50.30 | -53.35 | -52.17 | -23.43 | -36.97 | -34.05 | -34.29 | -30.66 | -41.21 | -38.79 | -43.07 | -34.94 | -40.38 | -36.86 | -13.29 | -5.43 | -7.03 |
Current Ratio |
1.3 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | 1.0 | 0.9 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.0 | - | 1.1 | 1.2 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 2.5 | 2.5 | 2.5 | 2.5 | 5.8 | 5.8 | 5.8 | 5.8 | 8.7 | 8.7 | 8.7 | 8.7 | 3.7 | 3.7 | 3.7 | 3.7 | 11.4 | 11.4 | 11.4 | 11.4 | 7.5 | 7.5 | 7.5 | 7.5 | 2.8 | 2.8 | 2.8 | 2.8 | 1.9 | 1.9 | 1.9 | 1.9 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 |
DSO |
66.4 | 56.0 | 58.1 | 63.2 | - | 60.4 | 43.6 | 59.9 | - | 33.2 | 63.0 | 65.4 | - | 3.8 | 4.8 | 20.7 | - | 14.0 | 11.0 | 13.5 | 18.7 | 24.3 | 29.4 | 22.2 | 19.0 | 19.4 | 30.5 | 28.2 | 24.4 | 248.1 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | 13.9 | - | - |
DIO |
26.4 | 34.0 | 44.1 | 93.7 | - | 89.0 | 120.7 | 153.0 | - | 112.7 | 140.7 | 287.2 | - | 144.3 | 105.2 | 320.7 | - | 296.0 | 238.7 | 295.6 | - | 329.5 | 375.7 | 451.2 | - | 986.3 | 1188.6 | 1096.2 | - | 16030.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
34.5 | 50.9 | 64.2 | 120.8 | - | 80.6 | 103.2 | 111.7 | - | 76.7 | 73.9 | 176.6 | - | 50.7 | 73.6 | 249.6 | - | 151.3 | 148.5 | 192.9 | - | 227.7 | 259.6 | 349.3 | - | 873.2 | 1052.2 | 1493.9 | - | 39769.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 102.2 | 156.9 | - | 149.4 | 164.3 | 212.9 | - | 145.8 | 203.7 | 352.6 | - | 148.1 | 110.0 | 341.4 | - | 310.0 | 249.7 | 309.1 | 18.7 | 353.8 | 405.1 | 473.4 | 19.0 | 1005.8 | 1219.0 | 1124.4 | 24.4 | 16278.8 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | - | - | - |
Cash Conversion Cycle |
- | - | 38.0 | 36.1 | - | 68.9 | 61.1 | 101.2 | - | 69.2 | 129.8 | 176.0 | - | 97.4 | 36.4 | 91.8 | - | 158.8 | 101.2 | 116.2 | 18.7 | 126.1 | 145.5 | 124.1 | 19.0 | 132.6 | 166.8 | -369.6 | 24.4 | -23490.2 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Alnylam Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
